![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Biogen Gains Rights to Sage Therapeutics’ Zuranolone for $1.53 Billion
Biogen Gains Rights to Sage Therapeutics’ Zuranolone for $1.53 Billion
![Biogen-logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Biogen-logo.gif?t=1595365104&width=430)
Biogen will pay Sage Therapeutics $1.53 billion to jointly develop and sell zuranolone (SAGE-217), a treatment for major depressive disorder (MDD), postpartum depression, and other psychiatric disorders, and SAGE-324, a treatment for essential tremors and additional neurological disorders.
Under the deal, Sage will be eligible to receive future milestone-based payments totaling an estimated $1.6 billion.
An oral tablet meant to be taken daily, zuranolone is currently being evaluated in a U.S. phase 3 study. It previously received a Breakthrough Therapy designation for MDD.
Upcoming Events
-
21Oct